Analyst firms · Wolfe Research · NTLA
Wolfe Research NTLA price target and rating history
Intellia Therapeutics Inc. (NTLA) · Health Care
Wolfe Research rates Intellia Therapeutics Inc. (NTLA) Underperform with a $9 price target, as of its latest action on Jul 16, 2026. It has published 4 rating actions on NTLA since February 2024, including 1 upgrade and 2 downgrades. Across 3 firms with a NTLA price target in the last 12 months, the median target is $8. Wolfe Research's $9 is 13% above that.
- Current rating
- Underperform
- Price target
- $9
- Median target, all firms
- $8
- Actions on NTLA
- 4
Wolfe Research price target on NTLA
Every Wolfe Research rating on NTLA
- Jul 16, 2026
- Nov 12, 2025
- Apr 21, 2025
- Feb 15, 2024
How other firms rate NTLA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Underweight | $8 | Oct 6, 2026 |
| Wolfe Research | Underperform | $9 | Jul 16, 2026 |
| William Blair | Outperform | Mar 2, 2026 | |
| Evercore ISI | In-line | $8 | Nov 11, 2025 |
Questions about Wolfe Research and NTLA
- What is Wolfe Research's price target for NTLA?
- Wolfe Research's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $9, from its action on Jul 16, 2026.
- What is Wolfe Research's rating on NTLA?
- Wolfe Research rates NTLA Underperform, a bearish rating, as of Jul 16, 2026.
- When did Wolfe Research last change its view on NTLA?
- On Jul 16, 2026, Wolfe Research downgrades to Underperform from Peer Perform, price target $9.
- How does Wolfe Research's NTLA target compare with other analysts?
- Across 3 firms with a NTLA price target in the last 12 months, the median target is $8. Wolfe Research's $9 is 13% above that.
More NTLA rating histories
All Wolfe Research ratingsNTLA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.